Caladrius Biosciences Inc (NASDAQ: CLBSsuspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction (CMD). 
As previously communicated, the pandemic impacted the enrollment in the FREEDOM Trial coupled with supply chain issues making enrollment much slower and challenging to accelerate. 
The FREEDOM trial enrolled approximately one-third of …

Full story available on